Clinical and molecular characterization of Chilean patients with Léri-Weill dyschondrosteosis
Author
dc.contributor.author
Rodríguez, Fernando Adrián
es_CL
Author
dc.contributor.author
Unanue Morales, Nancy
Author
dc.contributor.author
Hernández Cárdenas, María Isabel
es_CL
Author
dc.contributor.author
Basaure, Javiera
es_CL
Author
dc.contributor.author
Heath, Karen Elise
es_CL
Author
dc.contributor.author
Cassorla Goluboff, Fernando
es_CL
Admission date
dc.date.accessioned
2014-01-23T20:16:22Z
Available date
dc.date.available
2014-01-23T20:16:22Z
Publication date
dc.date.issued
2013
Cita de ítem
dc.identifier.citation
J Pediatr Endocr Met 2013; 26(7-8): 729–734
en_US
Identifier
dc.identifier.other
DOI 10.1515/jpem-2013-0023
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/129160
General note
dc.description
Artículo de publicación ISI
en_US
Abstract
dc.description.abstract
Aim: L é ri-Weill dyschondrosteosis (LWD) is a mesomelic
dysplasia with disproportionate short stature associated
with short stature homeobox-containing gene (SHOX)
haploinsufficiency. The objective of this study was to
improve the diagnosis of patients with suspected LWD
through molecular analysis.
Methods: Twelve patients from 11 families with a clinical
diagnosis of LWD were analyzed with multiplex ligationdependent
probe amplification to detect deletions and
duplications of SHOX and its enhancer regions. High resolution
melting and sequencing was employed to screen for
mutations in SHOX coding exons.
Results: The molecular-based screening strategy applied
in these patients allowed detection of five SHOX deletions
and two previously unreported SHOX missense mutations.
Conclusion: Molecular studies confirmed the clinical diagnosis
of LWD in seven out of 12 patients, which provided
support for therapeutic decisions and improved genetic
counseling in their families.